Compare ADMA Biologics Inc (ADMA) vs American Water Works Company Inc (AWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs American Water Works Company Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while American Water Works Company Inc trades at $133.97 (market cap $26.33B). The key difference: American Water Works Company Inc is far larger — about 12.4× ADMA Biologics Inc's market cap, and American Water Works Company Inc pays a 2.66% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AWK | |
|---|---|---|
Market Cap | $2.13B | $26.33B |
Sector | Health | Utilities |
52-Week High | $20.38 | $147.00 |
52-Week Low | $7.60 | $121.13 |
Enterprise Value | $2.20B | $41.89B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AWK trades at $134.82, down 1.49% today, near the consensus price target of $134.50. The stock shows a bullish technical trend with strong moving averages, while recent earnings have been mixed with two misses in the last three quarters. Revenue grew to $5.14B in 2025, with a net income margin of 21.17%, and the company continues strategic acquisitions and infrastructure investments, as seen in recent news (PRNewsWire, June 30, 2026).
Outlook remains stable with analyst consensus leaning buy (46.66% buy ratings), but risks include high debt levels and regulatory pressures. The stock offers steady growth potential through capital investments, though margin pressures and interest expenses could limit upside. Investors should weigh the defensive utility sector appeal against valuation multiples like a P/E of 23.6.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
